Rhumbline Advisers lifted its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 6.4% during the first quarter, HoldingsChannel reports. The firm owned 253,949 shares of the biopharmaceutical company’s stock after buying an additional 15,164 shares during the period. Rhumbline Advisers’ holdings in Horizon Therapeutics were worth $6,712,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in HZNP. Bank of New York Mellon Corp grew its holdings in Horizon Therapeutics by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 863,146 shares of the biopharmaceutical company’s stock valued at $16,900,000 after purchasing an additional 21,982 shares during the period. Teachers Advisors LLC grew its holdings in Horizon Therapeutics by 1.4% in the third quarter. Teachers Advisors LLC now owns 1,208,358 shares of the biopharmaceutical company’s stock valued at $23,660,000 after purchasing an additional 16,484 shares during the period. Legal & General Group Plc grew its holdings in Horizon Therapeutics by 17.6% in the third quarter. Legal & General Group Plc now owns 67,632 shares of the biopharmaceutical company’s stock valued at $1,325,000 after purchasing an additional 10,121 shares during the period. Meeder Asset Management Inc. grew its holdings in Horizon Therapeutics by 631.9% in the fourth quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 8,588 shares during the period. Finally, James Investment Research Inc. acquired a new stake in Horizon Therapeutics in the fourth quarter valued at approximately $1,073,000. Institutional investors own 85.98% of the company’s stock.
HZNP has been the topic of several research analyst reports. BidaskClub lowered Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research raised Horizon Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 25th. Jefferies Financial Group raised their price objective on Horizon Therapeutics to $34.00 and gave the company a “buy” rating in a report on Friday, March 1st. Cowen set a $33.00 price objective on Horizon Therapeutics and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Morgan Stanley raised Horizon Therapeutics from an “equal weight” rating to an “overweight” rating and set a $32.00 price objective on the stock in a report on Friday, March 8th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $30.83.
In other news, EVP Geoffrey M. Curtis sold 10,080 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $21.21, for a total value of $213,796.80. Following the transaction, the executive vice president now owns 35,367 shares in the company, valued at $750,134.07. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company’s stock.
NASDAQ HZNP opened at $24.60 on Friday. The company has a market capitalization of $4.55 billion, a PE ratio of 13.44 and a beta of 1.09. Horizon Therapeutics PLC has a 1-year low of $15.32 and a 1-year high of $29.44. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90.
Horizon Therapeutics (NASDAQ:HZNP) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 earnings per share. On average, research analysts predict that Horizon Therapeutics PLC will post 1.64 earnings per share for the current fiscal year.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: Quick Ratio
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.